Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lung Cancer
Pembrolizumab Succeeds, Nivolumab Fails, as First-Line Therapy for Advanced NSCLC
By
Phoebe Starr
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Patients with non–small-cell lung cancer (NSCLC) who lack targetable
EGFR
or
ALK
mutations typically receive platinum-based doublet chemotherapy as first-line therapy. Two phase 3 clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress compared immunotherapy and platinum-based chemotherapy as first-line treatment for patients with NSCLC. In KEYNOTE-024, pembrolizumab (Keytruda) was superior to chemotherapy in terms of progression-free survival (PFS) and overall survival (OS), whereas in CheckMate-026, nivolumab (Opdivo) failed to improve PFS compared with chemotherapy.
Read Article
Approval of First Liquid Biopsy to Detect EGFR Mutations in Lung Cancer Can Improve Patient Outcomes
By
Jessica Miller
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
The first liquid biopsy used to detect gene mutations that are associated with non–small-cell lung cancer (NSCLC) was approved by the FDA. The cobas EGFR Mutation Test v2 (Roche Molecular Systems), a blood-based companion diagnostic for erlotinib (Tarceva), is indicated as an initial test to detect
EGFR
gene mutations in patients with NSCLC.
Read Article
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
Tyrosine kinase inhibitors (TKIs) are the mainstay of therapy for patients with epidermal growth factor receptor (
EGFR
) mutation–positive non–small-cell lung cancer (NSCLC), according to the updated National Comprehensive Cancer Network (NCCN) NSCLC guideline. The NCCN guideline recommends
EGFR
testing as part of a broad molecular profiling in patients with NSCLC.
Read Article
Osimertinib Effective for First-Line Treatment of EGFR Mutation–Positive NSCLC
By
Laura Morgan
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
The third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (Tagrisso) targets
EGFR
mutations, including
T790M
. Osimertinib was approved by the FDA in November 2015 for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and the
T790M
mutation whose disease progressed during or after EGFR TKI therapy.
Read Article
Aprepitant Reduces Cough Severity in Patients with Lung Cancer
By
Meg Barbor, MPH
Lung Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
Boston, MA—In a first-of-its-kind study, aprepitant (Emend), a centrally acting neurokinin (NK)-1 antagonist indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV), led to a reduction in cough frequency and an improvement in the objective and subjective measures of cough in patients with lung cancer.
Read Article
PROCLAIM Study Fails to Identify Best Regimen for Locally Advanced Lung Cancer
By
Alice Goodman
Lung Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
Read Article
DNA Blood Testing May Be an Alternative to Tumor Sampling for Identifying EGFR Mutations
By
Alice Goodman
Lung Cancer
May 2015, Vol 6, No 4
Geneva, Switzerland—Circulating DNA (ctDNA) in the blood of patients with cancer appears to detect lung cancer mutations, providing similar information to tumor tissue sampling, according to a study presented at the 2015 European Lung Cancer Conference. This makes blood testing for ctDNA an attractive option when tumor tissue sampling is not accessible.
Read Article
Approximately 1 in 4 Patients with Lung Cancer Are Not Tested for EGFR Mutations
By
Alice Goodman
Lung Cancer
May 2015, Vol 6, No 4
Geneva, Switzerland—A study with real-world data showed that almost 1 in 4 (24%) patients with advanced lung cancer are not receiving appropriate testing for EGFR mutations, even though guidelines recommend this genetic test to guide the selection of the most appropriate therapy.
Read Article
Postresection Routine Surveillance with CT Instead of Chest X-Ray Does Not Improve Survival in Early-Stage Lung Cancer
By
Rosemary Frei, MSc
Lung Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
Toronto, Canada—Survival is not improved with routine surveillance using computed tomography (CT) versus chest x-ray in patients who have undergone resection for stage I non–small-cell lung cancer (NSCLC), according to the results of a new analysis presented at the 2014 American Association for Thoracic Surgery meeting.
Read Article
Comparing the Safety and Efficacy of Stereotactic Radiotherapy versus Surgery in Lung Cancer
By
Laura Morgan
Lung Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—The use of stereotactic body radiotherapy (SBRT), also called stereotactic radiotherapy or radiosurgery, is an effective option for elderly patients with cancer who are inoperable or who decline surgery, but its safety and efficacy compared with surgery have not been investigated.
Read Article
Page 8 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma